Bi-Cheng Wang (Bicheng Wang)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 25

Top Topics

Combination Therapy

Systematic Review

Tyrosine Kinase

Liver Metastases

Top Venues

Journal of oncology

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies. Targeted oncology 19 (2) (2024)
Ru-Bo Cao, Yao Ge, Wen-Xuan Zhang, Guo-He Lin, Bo-Hua Kuang, Bi-Cheng Wang
The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies. Medicine 103 (31) (2024)
Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies. Targeted oncology 19 (2) (2024)
Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies. Targeted oncology 19 (2) (2024)
Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies. Targeted oncology (2024)
Ru-Bo Cao, Yao Ge, Wen-Xuan Zhang, Guo-He Lin, Bo-Hua Kuang, Bi-Cheng Wang
The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies. Medicine 103 (31) (2024)
Ru-Bo Cao, Yao Ge, Wen-Xuan Zhang, Guo-He Lin, Bo-Hua Kuang, Bi-Cheng Wang
The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies. Medicine 103 (31) (2024)
Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer. Medicine 102 (30) (2023)
Xin-Xiu Liu, Yan-Hong Han, Bo-Hua Kuang, Guo-He Lin, Bi-Cheng Wang
Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials. Medicine 102 (33) (2023)
Zhan-Jie Zhang, Liang-Liang Shi, Xiao-Hua Hong, Bo-Ya Xiao, Guo-He Lin, Quentin Liu, Bi-Cheng Wang
A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone. PloS one 17 (3) (2022)
Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin
Immunotherapy Alone or in Combination with Stereotactic Body Radiotherapy in Advanced Lung Cancer: A Pooled Analysis of Randomized Clinical Trials. Journal of oncology 2022 (2022)
Bi-Cheng Wang, Wen-Xuan Zhang, Bo-Hua Kuang, Guo-He Lin
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. PloS one 17 (10) (2022)
Bi-Cheng Wang, Bo-Ya Xiao, Bo-Hua Kuang, Guo-He Lin
The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies. Dermatologic therapy 35 (9) (2022)
Bo-Hua Kuang, Guo-He Lin, Quentin Liu, Bi-Cheng Wang
UHRF1 Induces Metastasis in Thyroid Cancer. Journal of oncology 2022 (2022)
Bi-Cheng Wang, Bo-Hua Kuang, Xin-Xiu Liu, Guo-He Lin
Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials. Medicine 101 (44) (2022)
Xin-Xiu Liu, Guo-He Lin, Bi-Cheng Wang
A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. Medicine 101 (45) (2022)
Bi-Cheng Wang, Bo-Ya Xiao, Peng-Cheng Li, Bo-Hua Kuang, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, Quentin Liu
Corrigendum to "Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis". Journal of oncology 2021 (2021)
Bi-Cheng Wang, Bo-Ya Xiao, Ji-Quan Fan, Guo-He Lin, Chang Wang, Quentin Liu, Yan-Xia Zhao
6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis. Medicine 100 (10) (2021)
Bo-Ya Xiao, Tong Su, Yu-Jia Huang, Guo-He Lin, Zhao-Bo Liu, Yun-Xiang Tang, Bi-Cheng Wang
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
Guohe Lin, Bi-Cheng Wang, Xiuwei Wu, Tong Sun, Lili Chen, Canliang Lu, Nianfei Wang
Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma. Cancer management and research 12 (2020)
Bi-Cheng Wang, Bo-Ya Xiao, Peng-Cheng Li, Bo-Hua Kuang, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, Quentin Liu
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Journal of oncology 2020 (2020)
Bi-Cheng Wang, Peng-Cheng Li, Ji-Quan Fan, Guo-He Lin, Quentin Liu
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis. Medicine 99 (28) (2020)
Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu
The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis. BMC cancer 20 (1) (2020)
Bi-Cheng Wang, Ru-Bo Cao, Pin-Dong Li, Chen Fu
The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. Cancer medicine 8 (13) (2019)
Bi-Cheng Wang, Chen Fu, Lin-Ka Xie, Bo-Hua Kuang, Yan-Xia Zhao
Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis. The Annals of pharmacotherapy 54 (6) (2019)